Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia

Annals of Hematology
Marc MichelXuena Wang

Abstract

Thrombopoietin receptor agonists increase platelet counts and reduce bleeding risk in patients with immune thrombocytopenia (ITP). Studies have reported that these agents may represent a risk factor for thromboembolic events, especially in the elderly, who are at increased risk for such complications relative to younger patients. In this retrospective analysis, efficacy and safety data for romiplostim in patients with ITP aged ≥65 years versus those aged <65 years are described. Data from 3 studies (N = 159; 24.5% ≥ 65 years of age) were analyzed for efficacy. Data from 13 studies (N = 1037; 28.4% ≥ 65 years of age) were analyzed for adverse events (AEs). Relative risk (RR) ratios with 95% CIs were calculated for duration-adjusted incidences of AEs for romiplostim versus placebo/standard of care (SOC) in patients ≥ 65 and <65 years. Slightly higher platelet response rates were seen among romiplostim-treated patients ≥ 65 versus <65 years. In the safety analyses, 65 (6.3%) received placebo/SOC, 69 (6.7%) received placebo/SOC and then romiplostim, and 903 (87.1%) received romiplostim only. Duration-adjusted AE rates were similar for romiplostim versus placebo/SOC in older and younger patients. The risks for grade ≥ 3 bleeding (RR...Continue Reading

References

Jul 1, 1988·The American Journal of the Medical Sciences·T H GuthrieL M Prisant
Jan 1, 1995·Acta Haematologica·M LinaresF Carbonell
Sep 6, 2003·British Journal of Haematology·Annette J NeylonUNKNOWN Northern Region Haematology Group
Oct 20, 2006·The New England Journal of Medicine·James B BusselJanet L Nichol
May 31, 2008·British Journal of Haematology·Carole Pierrot-Deseilligny DespujolBertrand Godeau
Oct 14, 2008·European Journal of Internal Medicine·Samira DaouEmmanuel Andrès
Nov 26, 2009·Hematology/oncology Clinics of North America·Patrick F Fogarty
Oct 20, 2010·British Journal of Haematology·Marianne T SeverinsenHenrik Toft Sørensen
Nov 12, 2010·The New England Journal of Medicine·David J KuterDietmar P Berger
Jun 20, 2014·Journal of Thrombosis and Haemostasis : JTH·M RuggeriUNKNOWN Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311

❮ Previous
Next ❯

Citations

Sep 1, 2016·Annals of Hematology·Eduardo AnguitaF Javier Martín-Sánchez
Feb 27, 2018·British Journal of Haematology·Francesco Rodeghiero
Dec 17, 2019·European Journal of Haematology·Tomás José González-LópezLuis Javier García-Frade
Apr 12, 2016·British Journal of Haematology·Matthieu MahévasBertrand Godeau
Mar 10, 2017·Annals of Hematology·Francesco Rodeghiero, Giuseppe Carli
Apr 1, 2021·Transplantation and Cellular Therapy·Georgios E ChristakopoulosAngela R Smith
Jul 28, 2021·Expert Opinion on Biological Therapy·Frederick ChenAdrian Newland

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.